Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring <i>EGFR</i> or <i>ALK</i> genetic aberration.

Gao, Guanghui; Ni, Jian; Wang, Yina; Ren, Shengxiang; Liu, Zhihua; Chen, Gongyan; Gu, Kangsheng; Zang, Aimin; Zhao, Jun; Guo, Renhua; He, Jianxing; Lin, Xiaoyan; Pan, Yueyin; Ma, Zhiyong; Wang, Zhehai; Fan, Min; Liu, Yunpeng; Cang, Shundong; Yang, Xinfeng; Li, Weixia; Wang, Quanren; Zhou, Caicun

Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration.

Gao, Guanghui; Ni, Jian; Wang, Yina; Ren, Shengxiang; Liu, Zhihua; Chen, Gongyan; Gu, Kangsheng; Zang, Aimin; Zhao, Jun; Guo, Renhua; He, Jianxing; Lin, Xiaoyan; Pan, Yueyin; Ma, Zhiyong; Wang, Zhehai; Fan, Min; Liu, Yunpeng; Cang, Shundong; Yang, Xinfeng; Li, Weixia; Wang, Quanren; Zhou, Caicun.

Afiliação

Gao G; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
Ni J; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
Wang Y; Department of Oncology, The First Affiliated Hospital Zhejiang University, Hangzhou, China.
Ren S; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
Liu Z; Thoracic Tumor Radiotherapy Department, Jiangxi Cancer Hospital, Nanchang, China.
Chen G; Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Gu K; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zang A; Department of Oncology, Affiliated Hospital of Hebei University, Hebei, China.
Zhao J; Department of Oncology, Beijing Cancer Hospital, Beijing, China.
Guo R; Department of Oncology, Jiangsu Province Hospital, Nanjing, China.
He J; Thoracic Surgery Department, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Lin X; Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China.
Pan Y; Department of Medical Oncology, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China.
Ma Z; Department of Oncology, Henan Cancer Hospital, Zhengzhou, China.
Wang Z; Department of Oncology, Shandong Cancer Hospital, Jinan, China.
Fan M; Radiation Oncology Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Cang S; Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, China.
Yang X; Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Li W; Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Wang Q; Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Zhou C; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.

Transl Lung Cancer Res ; 11(6): 964-974, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35832447

Palavras-chave

Apatinib; Camrelizumab; PD-L1 expression; immunotherapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Transl Lung Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China